MARKET

ZSAN

ZSAN

Zosano Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.020
-0.040
-3.77%
Pre Market: 0.9354 -0.0846 -8.29% 06:04 01/27 EST
OPEN
1.070
PREV CLOSE
1.060
HIGH
1.080
LOW
1.000
VOLUME
13.95K
TURNOVER
--
52 WEEK HIGH
1.960
52 WEEK LOW
0.3275
MARKET CAP
104.11M
P/E (TTM)
-1.0510
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Thinking about buying stock in Zosano Pharma, Senseonics, Tellurian, Cinedigm, or AMC Entertainment?
PR Newswire - PRF · 6d ago
Thinking about buying stock in Zosano Pharma, Senseonics, Tellurian, Cinedigm, or AMC Entertainment?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZSAN, SENS, TELL, CIDM, and AMC.
PR Newswire - PRF · 6d ago
Zosano Pharma (ZSAN) in Focus: Stock Moves 6.3% Higher
Zosano Pharma (ZSAN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Zacks · 01/12 14:08
Microneedle Drug Delivery Systems Market Worldwide Prospects, Share, Crucial Players, Size & Forecast 2020 - 2030
Jan 12, 2021 (MARKITWIRED via COMTEX) -- A recent market study published by Future Market Insights (FMI) on the microneedle drug delivery systems market...
Markitwired · 01/12 09:40
Mid-Afternoon Market Update: Dow Climbs 250 Points; Boston Private Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 0.83% to 30,474.00 while the NASDAQ rose 0.94% to 12,817.22. The S&P also rose, gaining 0.90% to 3,734.01.
Benzinga · 01/05 19:32
Mid-Day Market Update: Crude Oil Surges Over 4%; Generation Bio Shares Slide
Midway through trading Tuesday, the Dow traded up 0.21% to 30,288.13 while the NASDAQ rose 0.53% to 12,765.92. The S&P also rose, gaining 0.35% to 3,713.54.
Benzinga · 01/05 17:21
Thinking about buying stock in Zomedica, Zosano Pharma, TapImmune, Five Prime Therapeutics, or Inuvo?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, ZSAN, MRKR, FPRX, and INUV.
PR Newswire - PRF · 01/05 14:31
The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 4)
Benzinga · 01/05 13:38
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZSAN. Analyze the recent business situations of Zosano Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZSAN stock price target is 1.833 with a high estimate of 2.000 and a low estimate of 1.500.
EPS
Institutional Holdings
Institutions: 58
Institutional Holdings: 13.61M
% Owned: 13.33%
Shares Outstanding: 102.07M
TypeInstitutionsShares
Increased
14
4.34M
New
19
1.82M
Decreased
1
7.33K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/Director
John Walker
Chief Executive Officer/Director
Steven Lo
Chief Financial Officer
Christine Matthews
Senior Vice President
Dushyant Pathak
Vice President
Eric Scharin
Other
Thorsten von Stein
Director
Linda Grais
Director
Joseph Hagan
Independent Director
Steven Elms
Independent Director
Kenneth Greathouse
Independent Director
Kleanthis Xanthopoulos
  • Dividends
  • Splits
  • Insider Activity
No Data
About ZSAN
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing systemic administration of therapeutics to patients using its Adhesive Dermally-Applied Microarray (ADAM) technology. ADAM is an intracutaneous delivery system designed to offer drug absorption into the bloodstream. ADAM consists of an array of drug-coated titanium microneedles mounted on an adhesive backing that is pressed on to the skin using a reusable handheld applicator. The Company’s Qtrypta (M207) is a formulation of zolmitriptan delivered utilizing its ADAM technology. Qtrypta (M207) is being investigated as a treatment to provide relief of migraine symptoms in the migraine cycle. The Company has developed its transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications.

Webull offers kinds of Zosano Pharma Corp stock information, including NASDAQ:ZSAN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZSAN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZSAN stock methods without spending real money on the virtual paper trading platform.